drugset / Trial / NCT04584710
A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The proposed trial will obtain preliminary data on the feasibility of studying RTB101 as compared to placebo for COVID-19 post-exposure prophylaxis in adults age ≥ 65 years to inform the design of a subsequent pivotal trial.
Timeline
- Start
- 2020-10-13
- Primary completion
- 2021-02
- Completion
- 2021-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dactolisib | Small molecule | 10 mg | Oral |